<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-120609" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatopulmonary Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bansal</surname>
            <given-names>Kamna</given-names>
          </name>
          <aff>Baylor College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gore</surname>
            <given-names>Meghana</given-names>
          </name>
          <aff>Memorial Herman Hospital and Methodist West Hospital ,Katy, Tx</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mittal</surname>
            <given-names>Sahil</given-names>
          </name>
          <aff>Kelsey Seybold Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamna Bansal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Meghana Gore declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sahil Mittal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-120609.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hepatopulmonary syndrome is hypoxemia due to dilated intrapulmonary vasculature in the presence of liver disease or portal hypertension. It is a serious condition and can develop in any patient with chronic or acute liver disease. To avoid the high morbidity and mortality associated with this condition, it must be promptly diagnosed and treated. This activity reviews the evaluation and treatment of hepatopulmonary syndrome and highlights the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of hepatopulmonary syndrome.</p></list-item><list-item><p>Evaluate patients&#x000a0;with hepatopulmonary syndrome.</p></list-item><list-item><p>Compare&#x000a0;the management options available for hepatopulmonary syndrome.</p></list-item><list-item><p>Collaborate with an&#x000a0;interprofessional team to enhance the care of patients with hepatopulmonary syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=120609&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=120609">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-120609.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hepatopulmonary syndrome (HPS) was first proposed in 1977 based on autopsy and clinical findings. Autopsies showed dilated pulmonary vasculature in patients with liver cirrhosis and were thought to cause some of the pulmonary&#x000a0;manifestations seen in patients with chronic liver disease.<xref ref-type="bibr" rid="article-120609.r1">[1]</xref>&#x000a0;HPS is defined as reduced arterial oxygen saturation due to dilated pulmonary vasculature in the presence of advanced liver disease or portal hypertension.&#x000a0; &#x000a0;</p>
        <p>
<bold>Diagnostic criteria</bold>
</p>
        <p>The diagnostic criteria for HPS include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Partial pressure of oxygen (PaO2):</bold>&#x000a0;Less than 80 mm Hg while breathing room air, or alveolar-arterial oxygen gradient (A-aO2), &#x02265;15 mm while breathing room air; in patients over 64, A-aO2 &#x0003e;20 mm Hg is considered diagnostic&#x000a0;(they should be&#x000a0;resting in a seated position).</p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary vascular dilatation:</bold>&#x000a0;As shown by positive contrast-enhanced echocardiography or by radioactive lung-perfusion scanning (showing brain shunt fraction &#x0003e;6%)&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Portal hypertension:</bold>&#x000a0;With or without cirrhosis&#x000a0;<xref ref-type="bibr" rid="article-120609.r2">[2]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>The severity of HPS is based on PaO2 levels:<bold>&#x000a0;&#x000a0;</bold></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mild:&#x000a0;</bold>PaO2 &#x02265;80 mm Hg with A-aO2 &#x02265;15 mm Hg while breathing room air</p>
          </list-item>
          <list-item>
            <p><bold>Moderate:&#x000a0;</bold>PaO2 &#x02265;60 mm Hg to &#x0003c;80 mm Hg with A-aO2 &#x02265;15 mm Hg while breathing room air&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Severe:</bold>&#x000a0;PaO2 &#x02265;50 mm Hg to &#x0003c;60 mm Hg with A-aO2 &#x02265;15 mm Hg while breathing room air&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Very severe:</bold> PaO2 &#x0003c;50 mm Hg with A-aO2 &#x02265;15 mm Hg while breathing room air, or PaO2 &#x0003c;300 mm Hg while breathing 100% oxygen&#x000a0;<xref ref-type="bibr" rid="article-120609.r3">[3]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120609.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HPS is most commonly associated with portal hypertension due to&#x000a0;chronic liver disease or cirrhosis. However, portal hypertension without underlying liver disease can also cause HPS. Acute liver disease, like acute hepatitis resulting in acute liver failure, is a rare cause of HPS. The presence and severity of HPS do not correlate with the severity of liver disease.</p>
      </sec>
      <sec id="article-120609.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>HPS is more common in Whites than Hispanics or Blacks&#x000a0;and&#x000a0;is less common in patients who smoke.<xref ref-type="bibr" rid="article-120609.r4">[4]</xref>&#x000a0;The incidence of HPS in patients with cirrhosis, based on reports from liver transplantation centers, ranged from 5%&#x000a0;to 32%.<xref ref-type="bibr" rid="article-120609.r5">[5]</xref>&#x000a0;HPS particularly occurs in patients with cirrhotic portal hypertensive and severe hepatic dysfunction; it is rarely seen in children.<xref ref-type="bibr" rid="article-120609.r6">[6]</xref></p>
      </sec>
      <sec id="article-120609.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pulmonary vascular dilatation resulting from an imbalance between vasodilators and vasoconstrictors is thought to be the main&#x000a0;cause of HPS. The exact mechanism of vasodilation is not precise, and multiple studies are ongoing to elucidate the exact mechanism. Pulmonary endothelial nitric oxide synthetase (eNOS) stimulation occurs in the lungs&#x000a0;as a result of&#x000a0;increased hepatic production of endothelin 1 (ET1) and pulmonary endothelin B (ETB) due to stress. eNOS stimulation causes increased nitric oxide (NO) production, a potent vasodilator.&#x000a0;</p>
        <p>Translocation of intestinal bacteria and endotoxemia in liver disease patients leads to massive accumulation of macrophages and monocytes in the lungs. These macrophages release tumor necrosis factor-alpha (TNF-alpha) in pulmonary vessels, leading to inducible nitric oxide synthetase (iNOS) activation. iNOS stimulation also causes increased nitric oxide (NO) production. Bacterial accumulation and increased NO cause increased levels of heme oxygenase. Heme oxygenase causes the degradation of heme and leads to increased carbon monoxide (CO) production. Being potent vasodilators, this increased production of NO and CO plays a crucial role in pulmonary vasodilatation. Also, macrophages, monocytes, and TNF alpha activate vascular endothelial growth factor (VEGF), leading to increased angiogenesis in the pulmonary vasculature.<xref ref-type="bibr" rid="article-120609.r3">[3]</xref><xref ref-type="bibr" rid="article-120609.r7">[7]</xref>&#x000a0;</p>
        <p>Vasodilation and angiogenesis lead to arteriovenous (AV) shunt formation within pulmonary vasculature, leading to a mismatch of ventilation-perfusion. The pulmonary capillaries are dilated to 15&#x000a0;to 500 mm in HPS compared to a normal diameter between 8&#x000a0;and 15 mm.<xref ref-type="bibr" rid="article-120609.r8">[8]</xref><xref ref-type="bibr" rid="article-120609.r9">[9]</xref>&#x000a0;Dilatation of pulmonary vasculature leads to reduced transit time for blood cells and a large amount of blood passing through pulmonary vasculature without undergoing gas exchange.&#x000a0;Some blood may pass through AV shunts without encountering alveoli, so gas exchange does not happen in these blood cells. Increased pulmonary capillary wall thickness has also been observed, which causes impaired diffusion of gases.&#x000a0; &#x000a0;</p>
        <p>This pulmonary vasodilation, AV shunts, and impaired diffusion lead to ventilation-perfusion mismatch, creating increased alveolar-arterial gradient and hypoxemia.<xref ref-type="bibr" rid="article-120609.r10">[10]</xref><xref ref-type="bibr" rid="article-120609.r11">[11]</xref>&#x000a0;Pulmonary vasodilation is most distinct in the lung bases, elucidating the symptoms like platypnoea and orthodeoxia associated with HPS. &#x000a0;</p>
        <p>Two types of HPS have been identified based on the location of dilated pulmonary vessels:&#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type I:</bold>&#x000a0;Dilatation of vessels at the precapillary levels near gas exchange units of the lungs; supplemental O2 increases PaO2 in this type of HPS &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Type II:</bold>&#x000a0;Larger dilatation of vessels causing arteriovenous shunts away from gas exchange units of lungs; supplemental O2 is not helpful&#x000a0;<xref ref-type="bibr" rid="article-120609.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120609.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The patient usually presents with dyspnea in the setting of liver disease. The onset is insidious, and dyspnea worsens with exertion. In the early stages, most patients are asymptomatic. The patient may have associated signs and symptoms of chronic liver disease.&#x000a0; &#x000a0;</p>
        <p>HPS may co-occur with other cardiopulmonary diseases, which can exacerbate ventilation-perfusion abnormalities.&#x000a0;The physical exam may show the following:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Cyanosis&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Digital clubbing <xref ref-type="bibr" rid="article-120609.r13">[13]</xref><xref ref-type="bibr" rid="article-120609.r14">[14]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Diffuse telangiectasia:</bold>&#x000a0;In several studies, spider naevi are more likely associated with HPS.<xref ref-type="bibr" rid="article-120609.r7">[7]</xref><xref ref-type="bibr" rid="article-120609.r15">[15]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Platypnoea:</bold> Worsening of dyspnea when moving from a supine to an upright position&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Orthodeoxia:</bold> Decrease in PaO2 of more than 5% or more than 4 mm Hg when moving from supine to upright; orthodeoxia is very specific for HPS in the presence of liver disease&#x000a0;(the sensitivity of orthodeoxia is low but increases with the severity of HPS).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120609.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There are several methods of evaluating patients for HPS.</p>
        <p>
<bold>Pulse Oximeter&#x000a0;</bold>
</p>
        <p>The initial screening for HPS involves using&#x000a0;a pulse oximeter&#x000a0;to evaluate PaO2. An O2 saturation of less than 96% signifies PaO2 less than 70 mm Hg and is considered a positive screen. If the screen is positive, the patient should undergo arterial blood gas (ABG) analysis, which helps to determine PaO2 and A-aO2.&#x000a0; &#x000a0;</p>
        <p>
<bold>Contrast-enhanced Echocardiography</bold>
</p>
        <p>Contrast-enhanced echocardiography with agitated saline&#x000a0;is the gold standard for diagnosing pulmonary vascular dilatation. Normal saline is agitated to generate microbubbles &#x0003e;10 micrometers in diameter. Normal saline is injected into a peripheral vein in the arm, and simultaneous transthoracic echocardiography (TTE) is performed. Usually, microbubbles are trapped in the pulmonary circulation and absorbed by the alveoli. However, in the presence of pulmonary dilatation and AV shunts, microbubbles evade pulmonary capture and reach the left atria of the heart, which can be seen via TTE in the left atrial chamber. The appearance of microbubbles in the left atria between the 4th and 6th cardiac cycle indicates pulmonary vasodilatation. If the microbubbles appear on the heart's left side before the 3rd cardiac cycle, it shows intracardiac shunting.&#x000a0; &#x000a0;</p>
        <p>
<bold>Transesophageal Echocardiogram</bold>
</p>
        <p>A transesophageal echocardiogram study<bold>&#x000a0;</bold>is superior to transthoracic echocardiography in diagnosing pulmonary dilation and intracardiac shunting. However, this test is invasive and riskier due to esophageal varices in many patients with cirrhosis and portal hypertension.&#x000a0; &#x000a0;</p>
        <p>
<bold>Radioactive Lung Perfusion Scanning</bold>
</p>
        <p>Radioactive lung perfusion scanning&#x000a0;is another test to establish pulmonary vessel dilatation. However, it is not as sensitive as contrast-enhanced echocardiography. This test does not distinguish between intrapulmonary and intracardiac shunting. It may be useful in deciding if HPS is contributing to hypoxemia in patients with concomitant lung disease. Radiolabeled albumin aggregates measuring approximately 20 micrometers in diameter are infused into the peripheral vein. Normally, particles of this size are trapped in the pulmonary microvasculature, and scintigraphy reveals nearly complete uptake in the lungs. When there is the existence of notable intrapulmonary shunting, some fraction of the albumin passes through the pulmonary vasculature and into the systemic circulation. Scintigraphy can reveal uptake in other organs besides the lung, which allows the calculation of the shunt fraction.&#x000a0;Brain shunt fraction &#x0003e;6% is considered significant.&#x000a0;&#x000a0;</p>
        <p>
<bold>Pulmonary Angiography</bold>
</p>
        <p>Pulmonary angiography&#x000a0;can diagnose and distinguish between type I and type II HPS. However, it is a more expensive&#x000a0;and invasive test, so it is not a preferred method of diagnosis. It is also less sensitive than contrast-enhanced echocardiography with agitated saline.&#x000a0;&#x000a0;</p>
        <p>
<bold>Additional Tests</bold>
</p>
        <p>Additional tests include chest X-rays, computed tomography (CT), and pulmonary function tests&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Chest X-ray:</bold>&#x000a0;May be normal or show increased bibasilar nodular opacities coinciding with increased pulmonary dilatation&#x000a0;(can&#x000a0;exclude coexistent pulmonary pathology)&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>CT of the chest:</bold>&#x000a0;May show enlarged dilated vessels; usually done to exclude pulmonary pathology&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary function tests:</bold>&#x000a0;May show decreased diffusion capacity for carbon monoxide (DLCO)&#x000a0;<xref ref-type="bibr" rid="article-120609.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120609.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Oxygen Therapy&#x000a0;</bold>
</p>
        <p>Oxygen therapy&#x000a0;is recommended for patients with severe hypoxemia. It is usually given until a more definitive treatment like liver transplantation can be performed. An increase in oxygenation and reduction in hypoxemia leads to better exercise tolerance and improved quality of life.&#x000a0;&#x000a0;</p>
        <p>
<bold>Liver Transplantation</bold>
</p>
        <p>Liver transplantation&#x000a0;is the only established treatment shown to provide long-term survival benefits for patients with HPS; it improves hypoxemia in 6&#x000a0;to 12 months. Studies have shown that PaO2 and A-aO2 reverse rapidly after transplant, mostly within&#x000a0;6 months. Intrapulmonary shunts also reverse but may take longer than 6 months. DLCO has also been shown to improve in some patients in one study.<xref ref-type="bibr" rid="article-120609.r17">[17]</xref>&#x000a0;</p>
        <p>Chronic liver disease patients with a&#x000a0;model for end-stage liver disease (MELD) score of 15 or greater are referred for liver transplant evaluation. Patients with HPS get exception points added to the MELD score to move them higher on the waiting list for liver transplantation. It is recommended that patients should undergo liver transplantation before the development of severe disease. &#x000a0;</p>
        <p>
<bold>Other Treatments</bold>
</p>
        <p>There is currently no medical therapy approved for HPS. Many medical treatments, including garlic, pentoxifylline, mycophenolate mofetil, aspirin, methylene blue, inhaled nitric oxide, nitric oxide inhibitors, and somatostatin, have been tried; however, none&#x000a0;have been of conclusive benefit&#x000a0;not FDA-approved.</p>
        <p>
<bold>Transjugular intrahepatic portosystemic shunt&#x000a0;</bold>
</p>
        <p>Limited data exist on transjugular intrahepatic portosystemic shunt (TIPS) use, and clinical outcomes can vary. TIPS can aggravate the hyperkinetic circulatory state, increasing intrapulmonary vasodilatation and shunting and worsening hypoxemia. There is also the risk of hepatic decompensation and encephalopathy after TIPS.&#x000a0;&#x000a0;</p>
        <p>
<bold>Pulmonary arterial coil embolization</bold>
</p>
        <p>The use of this procedure&#x000a0;is limited, as it can only be used in selected cases where there are large AV communications.</p>
      </sec>
      <sec id="article-120609.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for HPS include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Portopulmonary hypertension&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Atelectasis&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recurrent pulmonary emboli&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Atrial septal defect&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Arteriovenous malformations&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Post-pneumonectomy&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic cardiopulmonary disease&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pneumonitis&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pneumonia&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatic hydrothorax&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ascites causing reduced pulmonary functions</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120609.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with HPS have 2 times higher mortality compared&#x000a0;with patients with cirrhosis without HPS.&#x000a0;The condition is associated with a poor quality of life and inferior functional status.<xref ref-type="bibr" rid="article-120609.r4">[4]</xref>&#x000a0;The average life span in a patient with HPS (10.5 months) is significantly reduced compared&#x000a0;with patients with chronic liver disease patients without HPS (40.8 months). The mortality risk increases with the severity of the disease, with a worse prognosis in patients with very severe disease.<xref ref-type="bibr" rid="article-120609.r18">[18]</xref>&#x000a0;Post&#x02013;liver transplant survival is also slightly reduced in patients with very severe HPS.</p>
      </sec>
      <sec id="article-120609.s11" sec-type="Complications">
        <title>Complications</title>
        <p>HPS is a fatal disease that drastically reduces the life span of a patient with liver disease. Most patients will have progressive vasodilation and worsening hypoxemia. Without liver transplantation, death is inevitable, as no other medical therapies are currently available.&#x000a0; &#x000a0;</p>
        <p>Post&#x02013;liver transplantation, 80% to 85% of patients will have improved oxygenation and decreased AV shunts; however, certain patients can develop complications, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Refractory hepatopulmonary syndrome:</bold> Patients fail to improve oxygenation or develop recurrent HPS after liver transplantation.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Severe post-transplant hypoxemia:</bold> A&#x000a0;failure to maintain oxygen saturation above 85%, even on 100% oxygen&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Post-transplant portopulmonary hypertension:</bold> A rare complication</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120609.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Primary clinicians should screen all patients for alcohol abuse and intravenous drug use. Patients should be educated regarding the harmful effects of intravenous drug use, an overdose of medications like acetaminophen, and excessive alcohol consumption. Resources for rehabilitation for these should be offered. High-risk patients should be screened annually for viral hepatitis.</p>
      </sec>
      <sec id="article-120609.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of patients with HPS requires a strong interprofessional team approach involving hepatologists, pulmonologists, transplant surgeons, addiction medicine specialists, primary clinicians, pharmacists, social workers, and nurse educators. Prompt diagnosis and early liver transplant are the only way to alter the course of this fatal disease.</p>
      </sec>
      <sec id="article-120609.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=120609&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=120609">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/hepatopulmonary-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=120609">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/120609/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=120609">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-120609.s15">
        <title>References</title>
        <ref id="article-120609.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennedy</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Knudson</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis.</article-title>
            <source>Chest</source>
            <year>1977</year>
            <month>Sep</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-9</page-range>
            <pub-id pub-id-type="pmid">891282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krowka</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fuhrmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Heimbach</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension.</article-title>
            <source>Transplantation</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>7</issue>
            <fpage>1440</fpage>
            <page-range>1440-52</page-range>
            <pub-id pub-id-type="pmid">27326810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Roisin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary syndrome--a liver-induced lung vascular disorder.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>May</month>
            <day>29</day>
            <volume>358</volume>
            <issue>22</issue>
            <fpage>2378</fpage>
            <page-range>2378-87</page-range>
            <pub-id pub-id-type="pmid">18509123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Trotter</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zacks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Kaplowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wille</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <collab>Pulmonary Vascular Complications of Liver Disease Study Group</collab>
            </person-group>
            <article-title>Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates.</article-title>
            <source>Gastroenterology</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>135</volume>
            <issue>4</issue>
            <fpage>1168</fpage>
            <page-range>1168-75</page-range>
            <pub-id pub-id-type="pmid">18644373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schenk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuhrmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Madl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Funk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lehr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kandel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences.</article-title>
            <source>Gut</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>853</fpage>
            <page-range>853-9</page-range>
            <pub-id pub-id-type="pmid">12427789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oguz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sucak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dalgic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Atasever</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary syndrome in children with cirrhotic and non-cirrhotic portal hypertension: a single-center experience.</article-title>
            <source>Dig Dis Sci</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>175</fpage>
            <page-range>175-81</page-range>
            <pub-id pub-id-type="pmid">21792618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soulaidopoulos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cholongitas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giannakoulas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vlachou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goulis</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Review article: Update on current and emergent data on hepatopulmonary syndrome.</article-title>
            <source>World J Gastroenterol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>28</day>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1285</fpage>
            <page-range>1285-1298</page-range>
            <pub-id pub-id-type="pmid">29599604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schraufnagel</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Structural and pathologic changes in the lung vasculature in chronic liver disease.</article-title>
            <source>Clin Chest Med</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">8665783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez-Roisin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Agusti</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Mastai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1987</year>
            <month>May</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>1085</fpage>
            <page-range>1085-92</page-range>
            <pub-id pub-id-type="pmid">3579008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Roisin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Agust&#x000ed;</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary Disorders: Gas Exchange and Vascular Manifestations in Chronic Liver Disease.</article-title>
            <source>Compr Physiol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>25</day>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>711</fpage>
            <page-range>711-729</page-range>
            <pub-id pub-id-type="pmid">29687908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grilo-Bensusan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pascasio-Acevedo</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary syndrome: What we know and what we would like to know.</article-title>
            <source>World J Gastroenterol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>07</day>
            <volume>22</volume>
            <issue>25</issue>
            <fpage>5728</fpage>
            <page-range>5728-41</page-range>
            <pub-id pub-id-type="pmid">27433086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krowka</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation.</article-title>
            <source>Hepatology</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>138</fpage>
            <page-range>138-42</page-range>
            <pub-id pub-id-type="pmid">2403962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammad Alizadeh</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Fatemi</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mirzaee</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khoshbaten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Talebipour</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sharifian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khoram</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haj-sheikh-oleslami</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gholamreza-shirazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zali</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of hepatopulmonary syndrome in cirrhotic patients.</article-title>
            <source>World J Gastroenterol</source>
            <year>2006</year>
            <month>Mar</month>
            <day>28</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>1954</fpage>
            <page-range>1954-6</page-range>
            <pub-id pub-id-type="pmid">16610006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anand</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Seth</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Hepatopulmonary syndrome: prevalence and clinical profile.</article-title>
            <source>Indian J Gastroenterol</source>
            <year>2001</year>
            <season>Jan-Feb</season>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-7</page-range>
            <pub-id pub-id-type="pmid">11206870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silv&#x000e9;rio</surname>
                <given-names>Ade O</given-names>
              </name>
              <name>
                <surname>Guimar&#x000e3;es</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Milanez</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Naves</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Are the spider angiomas skin markers of hepatopulmonary syndrome?</article-title>
            <source>Arq Gastroenterol</source>
            <year>2013</year>
            <season>Jul-Sep</season>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-9</page-range>
            <pub-id pub-id-type="pmid">24322187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machicao</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Balakrishnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary complications in chronic liver disease.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>1627</fpage>
            <page-range>1627-37</page-range>
            <pub-id pub-id-type="pmid">24089295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascasio</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grilo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Pardo</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Ortega-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tirado</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rodriguez-Puras</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Sayago</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Bravo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Grilo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1391</fpage>
            <page-range>1391-9</page-range>
            <pub-id pub-id-type="pmid">24730359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120609.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swanson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Natural history of hepatopulmonary syndrome: Impact of liver transplantation.</article-title>
            <source>Hepatology</source>
            <year>2005</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>1122</fpage>
            <page-range>1122-9</page-range>
            <pub-id pub-id-type="pmid">15828054</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
